Atractylenolide II Suppresses Glycolysis and Induces Apoptosis by Blocking the PADI3-ERK Signaling Pathway in Endometrial Cancer Cells
Molecules · 21.02.2024 · 29 (5) · 939
DOI: 10.3390/molecules29050939 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 21.02.2024. Verfasst von Shuang Tian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, College of Integrated Chinese and Western Medical, Liaoning University of Traditional Chinese Medicine, Shenyang 110847, Chi…. Hauptthemen laut MEDLINE: Signal Transduction, Endometrial Neoplasms, Lactones, Sesquiterpenes. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Plan Projects of Liaoning Province.
Abstract (Originalsprache)
Atractylenolide II (AT-II), the major bioactive compound of Atractylodes macrocephala, exhibits anti-cancer activity against many types of tumors, but the roles and the potential mechanisms in endometrial cancer remain unclear. In the present study, AT-II treatment was found to significantly suppress RL95-2 and AN3CA cell proliferation and glycolysis, and induced their apoptosis by inactivating the ERK signaling pathway, accompanied by the changing expression of the glycolytic key enzymes and apoptotic-related proteins. Peptidyl arginine deiminase 3 (PADI3), as the candidate target gene of AT-II, was highly expressed in the endometrial cancer tissues and associated with a poor prognosis according to bioinformatics analysis. PADI3 knockdown inhibited proliferation and glycolysis in endometrial cancer cells and induced cell apoptosis. Furthermore, AT-II negatively regulated the expression of PADI3, and PADI3 overexpression reversed the effects of AT-II on endometrial cancer cells. Our findings suggested that the anti-cancer function of AT-II is associated with the suppression of glycolysis and induction of apoptosis by blocking the PADI3-ERK signaling pathway. Thus, AT-II represents a novel therapeutic target for endometrial cancer and targeting AT-II may serve as a potential strategy for the clinical therapy of endometrial cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, College of Integrated Chinese and Western Medical, Liaoning University of Traditional Chinese Medicine, Shenyang 110847, China.
- Department of Cell Biology and Genetics, Basic Medical College, Jinzhou Medical University, Jinzhou 121001, China.
- Department of Neurobiology, Basic Medical College, Jinzhou Medical University, Jinzhou 121001, China.
Förderung
- National Natural Science Foundation of China
- Science and Technology Plan Projects of Liaoning Province
Zitieren
APA
Tian, S., Ren, L., Liu, C., & Wang, Z. (2024). Atractylenolide II Suppresses Glycolysis and Induces Apoptosis by Blocking the PADI3-ERK Signaling Pathway in Endometrial Cancer Cells. Molecules, 29(5), 939. https://doi.org/10.3390/molecules29050939
Vancouver
Tian S, Ren L, Liu C, Wang Z. Atractylenolide II Suppresses Glycolysis and Induces Apoptosis by Blocking the PADI3-ERK Signaling Pathway in Endometrial Cancer Cells. Molecules. 2024;29(5):939. doi:10.3390/molecules29050939
BibTeX
@article{Tian2024,
author = {Tian, Shuang and Ren, Lili and Liu, Chao and Wang, Zhe},
title = {Atractylenolide II Suppresses Glycolysis and Induces Apoptosis by Blocking the PADI3-ERK Signaling Pathway in Endometrial Cancer Cells},
journal = {Molecules},
year = {2024},
volume = {29},
number = {5},
pages = {939},
doi = {10.3390/molecules29050939}
}
EUVIMED